Nieuws en video's - MEDIVIR B

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles PR Newswire STOCKHOLM, Oct. 5, 2023 Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 patients with >3 months follow-up Durable clinical benefit, median time to progression (to date) ~4.5 months with >50% of patients still on treatment Consistently good safety and tolerability profile...

Medivir to present at the Pareto Securities Healthcare Conference PR Newswire STOCKHOLM, Sweden, Sept. 14, 2023 STOCKHOLM , Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Pareto Securities Healthcare Conference, Today, September 14 , at 12.55 CET. CEO Jens Lindberg will give an updated...

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study PR Newswire STOCKHOLM, Sept. 11, 2023 STOCKHOLM , Sept. 11, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348. TNG348 is a novel...

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA PR Newswire STOCKHOLM, Sept. 7, 2023 STOCKHOLM , Sept. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical needs, today announces that data on the company's leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular...

Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire STOCKHOLM, Sept. 4, 2023 Central review of the 6 patients in phase 1b dose escalation part was performed In these 6 patients, complete response was recorded in 1 patient, partial response in 2 patients, and stable disease in 2 patients read by an independent radiologist using mRECIST The interim data from phase 1b further strengthens the...

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire STOCKHOLM, Sept. 1, 2023 STOCKHOLM , Sept. 1, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it will host a key opinion leader webcast on the current and future HCC (primary liver cancer) treatment landscape,...

Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM, Aug. 23, 2023 STOCKHOLM , Aug. 23, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, August 24, 2023 . CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with...

MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2023 PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM , Aug. 18, 2023 /PRNewswire/ -- Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima ® April – June Financial summary for the quarter Net turnover amounted to SEK 2.0 (0.5) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -26.3 (-21.5) million. Basic and diluted earnings per share amounted to...

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire STOCKHOLM, Aug. 14, 2023 Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment The patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor reduction maintained Consistently good safety and tolerability profile STOCKHOLM , Aug. 14, 2023 /PRNewswire/ -- Medivir AB (...

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire STOCKHOLM, Aug. 7, 2023 STOCKHOLM , Aug. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the formation of a Scientific Advisory Council as the company intensifies its plans for next phase of development. In February, Medivir announced...

Medivir's patent application for fostrox approved in China PR Newswire STOCKHOLM, June 19, 2023 STOCKHOLM , June 19, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the company's patent application, covering both substance claims for fostroxacitabine bralpamide (fostrox) and its use for liver cancer treatment, has recently been approved by the...

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima PR Newswire STOCKHOLM, June 2, 2023 STOCKHOLM , June 2, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that a safe dose has been established for treatment with the drug candidate fostroxacitabine bralpamide (fostrox)...

Medivir to present at the Redeye Growth Day PR Newswire STOCKHOLM, June 1, 2023 STOCKHOLM , June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Growth Day, today June 1, 2023 . CEO Jens Lindberg will participate in an In Focus interview led by Redeye analyst Richard Ramanius, with focus on our proprietary...

Change in the number of shares and votes in Medivir AB (publ) PR Newswire STOCKHOLM, May 31, 2023 STOCKHOLM , May 31, 2023 /PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, which was carried out as part of the long-term incentive...

Medivir to present at the ABGSC Life Science Summit PR Newswire STOCKHOLM, May 30, 2023 STOCKHOLM , May 30, 2023 /PRNewswire/ -- Medivir AB ( Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need , announces that the company will participate at the ABGSC Life Science Summit today May 30, 2023 . CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine...

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023 PR Newswire HUDDINGE, Sweden, May 16, 2023 HUDDINGE, Sweden , May 16, 2023 /PRNewswire/ -- In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 4 May 2023 ("LTIP 2023"), it is today announced that the board of directors of Medivir has resolved on (i) a share issue of 970,500 shares of series C, (ii) repurchase of the 970,500 shares of...

Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ) PR Newswire STOCKHOLM, May 4, 2023 STOCKHOLM , May 4, 2023 /PRNewswire/ -- The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023 , resolved to adopt new articles of association, whereby the share class A is removed and shares of series B are reclassified to ordinary shares. All of the company's existing shares as of today consist of shares of series B and there are...

Resolutions at the Annual General Meeting in Medivir on 4 May 2023 PR Newswire STOCKHOLM, May 4, 2023 STOCKHOLM , May 4, 2023 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023 . The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The annual general meeting in Medivir Aktiebolag (publ) resolved the following: Approval of profit...

MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023 PR Newswire HUDDINGE, Sweden, April 27, 2023 HUDDINGE, Sweden , April 27, 2023 /PRNewswire/ -- "Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase 2a part of the combination study with fostrox and Lenvima® in HCC after completed dose escalation" January – March Financial summary for the quarter Net turnover amounted to SEK 0.4 (0.5) million. The loss before interest, tax,...

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination PR Newswire STOCKHOLM, April 17, 2023 STOCKHOLM , April 17, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that a poster entitled 'A triple combination of fostrox (MIV-818) with immune checkpoint and kinase...